BeOne Medicines(BEIGF)
CA - San CarlosBiotechnology
Focus: BeOne Medicines is a publicly traded biotechnology company with 12,000 employees focused on small molecules and monoclonal antibodies across oncology, nephrology, immunology, and dermatology. The company is anchored by BRUKINSA (zanubrutinib), a BTK inhibitor generating $801M in Part D spending.
Profile data last refreshed 6h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Employees
12,000
Open Jobs
255+47 this month
Hot — 179 jobs added in 30d
Net +47 (179 new, 132 removed). Aggressive expansion phase.
Should You Work at BeOne Medicines?
AI assessmentStrong pipeline depth and growth trajectory make this a compelling mid-to-late stage oncology bet, but single-product revenue dependency and consistent losses create medium-term career risk unless Phase 3 programs advance rapidly.
Why Work Here
- Strong revenue growth ($1.4B to $2.5B YoY) and 72% R&D intensity signals commitment to pipeline expansion with 162 active job openings across R&D, Commercial, and Medical Affairs.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$2.5B
Key Products
$801M Part D spendingGrowing
Growth
Help build intelligence for BeOne Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.